Presentation is loading. Please wait.

Presentation is loading. Please wait.

Carlos Gomez-Roca, MD, Christophe M

Published byปฏิภาณ หงสกุล Modified over 5 years ago

Similar presentations

Presentation on theme: "Carlos Gomez-Roca, MD, Christophe M"— Presentation transcript:

1 Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites 
Carlos Gomez-Roca, MD, Christophe M. Raynaud, PhD, Frederique Penault-Llorca, MD, PhD, Olaf Mercier, MD, Frederic Commo, PhD, Luc Morat, PhD, Laure Sabatier, PhD, Philipe Dartevelle, MD, Estelle Taranchon, MS, Benjamin Besse, PhD, MD, Pierre Validire, MD, Antoine Italiano, MD, Jean-Charles Soria, PhD, MD  Journal of Thoracic Oncology  Volume 4, Issue 10, Pages (October 2009) DOI: /JTO.0b013e3181b44321 Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Difference in EGFR (A), VEGFR (B), ERCC1 (C), and Ki-67 (D) expression for each patient between primary tumor and corresponding metastasis (expressed in log2 [ratio]; ratio: score metastasis/score primary). Red represents increase in expression, and green represents decrease (both from 0 to 10 fold). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181b44321) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Biomarkers expression between primary tumor and the corresponding metastasis. Panels A and B, primary tumor with positive membranous staining for epidermal growth factor receptor (A) and the corresponding negative metastasis (B) (200× and 100×, respectively). Panels C and D, primary tumor with positive nuclear staining for excision repair crosscomplementing (C) and the corresponding negative metastasis (D) (200×). Panels E and F: primary tumor with membranous staining for vascular endothelial growth factor receptor (E) and the corresponding metastasis (F), both positive but with a diminished VEGFR expression at the metastatic sample (200×). Panels G and H: primary tumor and corresponding metastasis with nuclear staining for Ki-67, with a similar level of Ki-67 expression (200×). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181b44321) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Carlos Gomez-Roca, MD, Christophe M"

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma  Hideyuki Imoto, MD, Toshihiro.

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma  Hideyuki Imoto, MD, Toshihiro.
Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?  Tony Sourisseau, PhD, Khaled.

Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?  Tony Sourisseau, PhD, Khaled.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung  Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung  Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer  David R. Gandara, MD,

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer  David R. Gandara, MD,
Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy  Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,

Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy  Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion  Eckart Laack, MD, Ronald.

Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion  Eckart Laack, MD, Ronald.
Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers

Similar presentations

Ads by Google